Evidence map›Paper›PMID 38017545›Full record

ArticleMolecular cancer2023

Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors.

Pere Llinàs-Arias, Miquel Ensenyat-Mendez, Sandra Íñiguez-Muñoz, Javier I J Orozco, Betsy Valdez, Matthew P Salomon, Chikako Matsuba, Maria Solivellas-Pieras, Andrés F Bedoya-López, Borja Sesé and 11 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Multi-stage mechanisms of tumor metastasis and therapeutic strategies.Signal transduction and targeted therapy · 2024
    Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 4 countries.

Pere Llinàs-AriasCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Miquel Ensenyat-MendezCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Sandra Íñiguez-MuñozCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Javier I J OrozcoSaint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Betsy ValdezSaint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Matthew P SalomonKeck School of Medicine, USC Research Center for Liver Diseases, University of Southern California, Los Angeles, CA, USA.
Chikako MatsubaKeck School of Medicine, USC Research Center for Liver Diseases, University of Southern California, Los Angeles, CA, USA.
Maria Solivellas-PierasCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Andrés F Bedoya-LópezCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Borja SeséCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain.
Anja MezgerScience for Life Laboratory, Solna, 17665, Sweden.
Mattias OrmestadScience for Life Laboratory, Solna, 17665, Sweden.
Fernando UnzuetaAdvanced Optical Microscopy Facility Scientific and Technological Centres of University of Barcelona, Barcelona, Spain.
Siri H StrandDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Alexander D BoikoDepartment of Medicine, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, 90048, USA.
E Shelley HwangDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Javier CortésPangaea Oncology, Quiron Group, International Breast Cancer Center (IBCC), Barcelona, 08017, Spain.
Maggie L DiNomeDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Manel EstellerJosep Carreras Leukaemia Research Institute, Badalona, Barcelona, Catalonia, Spain.
Mathieu LupienPrincess Margaret Cancer Centre, Toronto, ON, M5G 1L7, Canada.
Diego M MarzeseCancer Epigenetics Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, 07120, Spain. diego.marzese@ssib.es.
Health Research Institute of the Balearic Islands · ESDuke University · USSaint John's Health Center · USScience for Life Laboratory · SEUniversity of Southern California · USCedars-Sinai Medical Center · USInstitució Catalana de Recerca i Estudis Avançats · ESOntario Institute for Cancer Research · CAStanford University · USUniversidad Europea de Madrid · ESUniversitat de Barcelona · ES

Funding

Govern de les Illes Balears Margalida ComasIDISBA - Impetus Call IMP21/10Instituto de Salud Carlos III CD22/00026Instituto de Salud Carlos III CPII22/00004
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which is the first step of the metastatic process.

methodsWe combined RNA expression and chromatin interaction data to identify insulator elements potentially associated with MMP gene expression and invasion. We employed CRISPR/Cas9 to disrupt the CCCTC-Binding Factor (CTCF) binding site on an insulator element downstream of the MMP8 gene (IE8) in two TNBC cellular models. We characterized these models by combining Hi-C, ATAC-seq, and RNA-seq with functional experiments to determine invasive ability. The potential of our findings to predict the progression of ductal carcinoma in situ (DCIS), was tested in data from clinical specimens.

resultsWe explored the clinical relevance of an insulator element located within the Chr11q22.2 locus, downstream of the MMP8 gene (IE8). This regulatory element resulted in a topologically associating domain (TAD) boundary that isolated nine MMP genes into two anti-correlated expression clusters. This expression pattern was associated with worse relapse-free (HR = 1.57 [1.06 - 2.33]; p = 0.023) and overall (HR = 2.65 [1.31 - 5.37], p = 0.005) survival of TNBC patients. After CRISPR/Cas9-mediated disruption of IE8, cancer cells showed a switch in the MMP expression signature, specifically downregulating the pro-invasive MMP1 gene and upregulating the antitumorigenic MMP8 gene, resulting in reduced invasive ability and collagen degradation. We observed that the MMP expression pattern predicts DCIS that eventually progresses into invasive ductal carcinomas (AUC = 0.77, p < 0.01).

conclusionOur study demonstrates how the activation of an IE near the MMP8 gene determines the regional transcriptional regulation of MMP genes with opposing functional activity, ultimately influencing the invasive properties of aggressive forms of breast cancer.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingTriple Negative Breast NeoplasmsChromatinFemaleHumansMatrix Metalloproteinase 8Multigene FamilyNeoplasm Recurrence, LocalChromatinMatrix Metalloproteinase 8ATAC-seqBreast cancerChromatincis-regulatory elementCTCFGene regulatory elementHi-CInsulatorInvasionMMP1MMP8RNA-seq

Identifiers

PMID38017545
PMCPMC10683115
OpenAlexW4389087702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.